{"id":1770,"date":"2022-09-27T15:12:08","date_gmt":"2022-09-27T15:12:08","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=1770"},"modified":"2026-02-23T00:43:08","modified_gmt":"2026-02-23T00:43:08","slug":"enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/","title":{"rendered":"Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence (Contributed by Dr. Antonis Antoniou)"},"content":{"rendered":"<p>Pathogenic variants in BARD1, RAD51C and RAD51D have recently been established as breast cancer susceptibility genes; and pathogenic variants in PALB2 have been shown to be associated with epithelial ovarian cancer risk. No cancer risk prediction model currently exists which incorporates these associations. Here, the BOADICEA multifactorial breast and ovarian cancer risk prediction model was extended to incorporate these associations and has been implemented in the CanRisk tool (www.canrisk.org) for use by healthcare professionals. The enhanced risk prediction model will enable healthcare professionals to provide personalised breast and epithelial ovarian cancer risks to BARD1, RAD51C, RAD51D and PALB2 pathogenic variant carriers and will allow for more informed choices on cancer risk management options. (<a href=\"https:\/\/jmg.bmj.com\/content\/early\/2022\/09\/21\/jmedgenet-2022-108471\">https:\/\/jmg.bmj.com\/content\/early\/2022\/09\/21\/jmedgenet-2022-108471<\/a> )<\/p>\n<p><a href=\"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/untitled-61\/\" rel=\"attachment wp-att-1771\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-1771\" src=\"https:\/\/blogs.bmj.com\/jmg\/files\/2022\/09\/Untitled-2-184x300.jpg\" alt=\"\" width=\"184\" height=\"300\" srcset=\"https:\/\/blogs.bmj.com\/jmg\/files\/2022\/09\/Untitled-2-184x300.jpg 184w, https:\/\/blogs.bmj.com\/jmg\/files\/2022\/09\/Untitled-2-629x1024.jpg 629w, https:\/\/blogs.bmj.com\/jmg\/files\/2022\/09\/Untitled-2-640x1041.jpg 640w, https:\/\/blogs.bmj.com\/jmg\/files\/2022\/09\/Untitled-2.jpg 678w\" sizes=\"auto, (max-width: 184px) 100vw, 184px\" \/><\/a><!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pathogenic variants in BARD1, RAD51C and RAD51D have recently been established as breast cancer susceptibility genes; and pathogenic variants in PALB2 have been shown to be associated with epithelial ovarian cancer risk. No cancer risk prediction model currently exists which incorporates these associations. Here, the BOADICEA multifactorial breast and ovarian cancer risk prediction model was [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1770","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence (Contributed by Dr. Antonis Antoniou) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence (Contributed by Dr. Antonis Antoniou) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"Pathogenic variants in BARD1, RAD51C and RAD51D have recently been established as breast cancer susceptibility genes; and pathogenic variants in PALB2 have been shown to be associated with epithelial ovarian cancer risk. No cancer risk prediction model currently exists which incorporates these associations. Here, the BOADICEA multifactorial breast and ovarian cancer risk prediction model was [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-27T15:12:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-23T00:43:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/jmg\/files\/2022\/09\/Untitled-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"678\" \/>\n\t<meta property=\"og:image:height\" content=\"1103\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/09\\\/27\\\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/09\\\/27\\\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence (Contributed by Dr. Antonis Antoniou)\",\"datePublished\":\"2022-09-27T15:12:08+00:00\",\"dateModified\":\"2026-02-23T00:43:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/09\\\/27\\\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\\\/\"},\"wordCount\":156,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/09\\\/27\\\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2022\\\/09\\\/Untitled-2-184x300.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/09\\\/27\\\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/09\\\/27\\\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/09\\\/27\\\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\\\/\",\"name\":\"Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence (Contributed by Dr. Antonis Antoniou) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/09\\\/27\\\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/09\\\/27\\\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2022\\\/09\\\/Untitled-2-184x300.jpg\",\"datePublished\":\"2022-09-27T15:12:08+00:00\",\"dateModified\":\"2026-02-23T00:43:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/09\\\/27\\\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/09\\\/27\\\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/09\\\/27\\\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2022\\\/09\\\/Untitled-2.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2022\\\/09\\\/Untitled-2.jpg\",\"width\":678,\"height\":1103},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/09\\\/27\\\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence (Contributed by Dr. Antonis Antoniou)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence (Contributed by Dr. Antonis Antoniou) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/","og_locale":"en_US","og_type":"article","og_title":"Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence (Contributed by Dr. Antonis Antoniou) - JMG Contact blog","og_description":"Pathogenic variants in BARD1, RAD51C and RAD51D have recently been established as breast cancer susceptibility genes; and pathogenic variants in PALB2 have been shown to be associated with epithelial ovarian cancer risk. No cancer risk prediction model currently exists which incorporates these associations. Here, the BOADICEA multifactorial breast and ovarian cancer risk prediction model was [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/","og_site_name":"JMG Contact blog","article_published_time":"2022-09-27T15:12:08+00:00","article_modified_time":"2026-02-23T00:43:08+00:00","og_image":[{"width":678,"height":1103,"url":"https:\/\/blogs.bmj.com\/jmg\/files\/2022\/09\/Untitled-2.jpg","type":"image\/jpeg"}],"author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence (Contributed by Dr. Antonis Antoniou)","datePublished":"2022-09-27T15:12:08+00:00","dateModified":"2026-02-23T00:43:08+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/"},"wordCount":156,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2022\/09\/Untitled-2-184x300.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/","url":"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/","name":"Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence (Contributed by Dr. Antonis Antoniou) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2022\/09\/Untitled-2-184x300.jpg","datePublished":"2022-09-27T15:12:08+00:00","dateModified":"2026-02-23T00:43:08+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/#primaryimage","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2022\/09\/Untitled-2.jpg","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2022\/09\/Untitled-2.jpg","width":678,"height":1103},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/09\/27\/enhancing-the-boadicea-cancer-risk-prediction-model-to-incorporate-new-data-on-rad51c-rad51d-bard1-updates-to-tumour-pathology-and-cancer-incidence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence (Contributed by Dr. Antonis Antoniou)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=1770"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1770\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=1770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=1770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=1770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}